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Abstract 
Cognitive deficits associated with Alzheimer's disease are known to result from 
decreases in acetylcholine within the cholinergic system of the medial septal area, which 
projects to the hippocampus. The significance of the neurotransmitter norepinephrine 
within this context has not been extensively reviewed. The present study measured the 
effects that Guanfacine, an alpha-2 noradrenergic agonist, has on memory deficits 
produced by cholinergic cell lesion in the rat medial septum. Memory processing during 
pre-lesion, post-lesion, and post-drug administration groups was quantified using a 
socially transmitted food preference task. Following administration ofthe cholinergic 
neurotoxin 192 IgG-saporin, subjects exhibited a significant decrease in memory 
formation when compared to baseline. Furthermore, following injection of guanfacine 
into post-lesioned rats, subjects displayed a significant value ofmemory formation above 
chance. Memory-related effectiveness ofguanfacine seems to be dependent on a baseline 
number of acetylcholine cells within the medial septum. Consequently, data suggests that 
guanfacine may carry no more therapeutic worth for patients afflicted by Alzheimer's 
disease than routinely prescribed acetylcholinesterase inhibitors. However, such 
conclusions must not be considered definitive by any means, as it is possible that future 
research might elaborate on possible cellular explanations for the increase in memory 
formation observed following guanfacine administration in the present examination. 
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Effects of Guanfacine on Mnemonic Processing Following Lesion to Rat Medial Septum: 
A Novel Treatment Approach to Alzheimer's Memory Type Deficits 
Mnemonic processing encompasses tasks related to the acquisition, integration, 
and recollection of information from cognition. The hippocampus (HPC) is the most 
widely accepted brain region associated with such memory (Agg1eton, Hunt, & Rawlins, 
1986; Astur, Taylor, Mame1ak, Philpott, & Sutherland, 2002; O'Keefe & Dostrovsky, 
1971; O'Keefe & Nadel, 1978). Within the HPC, acetylcholine (ACh) neurotransmission 
is coupled with forming novel memories (Whishaw, 1985; Kesner, 1998; White & 
MacDonald, 2002; Gold, 2004). The medial septum (MS), anatomically connected to the 
HPC, is the primary source ofACh to the HPC (Baxter, Vale-Martinez, & Eichenbaum, 
2002; Decker & McGaugh, 1991; Izquierdo, Dacunha, Rosat, Jerusa1insky, Ferreira, & 
Medina, 1992; Myhrer, 2003). Patients diagnosed with Alzheimer's disease (AD) display 
marked decreases in ACh functioning not seen in the normal aging populace (Bartus, 
Dean, Beer, & Lippa, 1982). Consequently, impairment of the ACh system and thus the 
MS are associated with memory deficits within the AD population (Rossor, Iversen, 
Johnson, Mountjoy, & Roth, 1981). 
The interaction of the norepinephrine (NE) neurotransmitter system with the ACh 
system in memory-related tasks has received much attention recently (Crutcher & Davis, 
1981; Decker & McGaugh, 1989; Sirvio, Riekkinen Jr., Va1jakka, Pitkanen, Partanen, & 
Riekkinen, 1990). Decker and colleagues (1989) suggest that a reduction in NE might 
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further increase memory deficits when coupled with an already degraded cholinergic 
innervation. The locus coeruleus (LC) is the primary brain area that supplies NE to the 
HPC (Loughlin, Foote, & Fallon, 1982; MacDonald & Scheinin, 1995; Nakamura & 
Sakaguchi; 1990). Therefore, a shortage ofNE from the LC might substantially 
contribute to the lack ofmemory function associated with AD (Bondareff, Mountjoy, & 
Roth, 1981, 1982; Chanpalay, 1991). 
One potential approach to treatment ofAlzheimer's might involve the 
pharmacological NE agonist Guanfacine, which has been shown to increase learning and 
memory in both rodent models and human studies (Arnsten, Cai, & Goldmanrakic, 1988; 
Arnsten & Contant, 1992; Jakala, Riekkinen, Sirvio, Koivisto, Kejonen, & Vanhanen, 
1999). Accordingly, Guanfacine administration might aid in delaying the onset of 
hippocampal-based memory AD-like brain impairments. In order to measure the effects 
that Guanfacine has on mnemonic processing, the present study involves lesioning the 
medial septum followed by administration of guanfacine within a rat population. 
Guanfacince is hypothesized to increase memory performance on a socially transmitted 
food preference task. 
Memory Systems 
Thirty years ago, a majority of memory systems were conceptualized as specific 
dichotomies. As a result, much disparity existed within the field ofneuroscience when 
defining such systems. For example, evidence was gathered exclusively for declarative 
and procedural memory systems (Cohen & Squire, 1980), explicit and implicit memory 
systems (Graf & Schacter, 1985), as well as memory and habit systems (Mishkin, 
Malamut, & Bachevalier, 1984). This means that individual memory dichotomies were 
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gaining support as separate entities, while the field ofmemory systems should have been 
integrating all dichotomies within a single more efficient taxonomy. It makes sense that 
subsequent studies have shown interactions existed between single components of several 
of the dichotomies, thus discrediting any single memory dichotomy as a reliable model. 
One such interaction involved a contrast between declarative memory and habit memory 
in amnesic patients (Knowlton, Mangels, & Squire, 1996). Consequently, there were 
many confounding interactions between differential brain areas believed to be involved in 
very specific memory systems. 
Recently, Squire (2004) elaborated on a reliable taxonomy, which accounts for 
relevant brain structures associated with different memory systems (see Figure 1). 
DECLARATIVE NONDECLARATIVE 
A
FACTS EVENTS 
EM:ODONAL SKELEtAl. 
RESPyNSES RESIrNSES 
SIMPLE 
CLASSICAL LEARNING 
PERCEPTUAL CONDITIONING 
LEARNING ~ 
MEDIAL TEMPORAL LOBE STRIATUM NEOCORTEX AMYGDALA CEREBELLUM REFLEX
 
DIENCEPHALON PATHWAYS
 
Figure. 1. A taxonomy of mammalian long-tenn memory systems. The taxonomy lists the brain structures 
thought to be especially important for each fonn ofdeclarative and nondeclarative memory. In addition to 
its central role in emotionalleaming, the amygdala is able to modulate the strength of both declarative and 
nondeclarative memory (adapted from Squire, 2004). 
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This taxonomy seems to be quite reliable and well respected within the literature. The 
classification divides memory very broadly into "declarative" and "nondeclarative" 
systems. "Declarative" memory is recollection-based, pertaining to facts and perceptions 
in regards to single events. This system is capable ofprocessing multiple pieces of 
information and is impaired in amnesic patients (Squire, 1992). Furthermore, the 
memory scheme is associated with operating in the medial tempora110be and 
diencephalon. "Nondeclarative" memory is responsible for extracting common 
perceptions from several isolated and serial events, allowing one to integrate information 
from variable contexts. This scheme is linked with the following brain areas: striatium, 
neocortex, amygdala, cerebellum, and reflex pathways. 
Many ofthe memory systems within the proposed anatomical taxonomy, which 
include specific brain regions, have been shown to function both independently and 
dependently (Packard & McGaugh, 1996; Tulving, Hayman, & MacDonald, 1991). The 
evolution from single memory dichotomies to a reliable taxonomy has led to the widely 
accepted discovery that the hippocampus is most definitely involved in declarative 
memory tasks. 
Hippocampus and memory: evidence from human studies 
Following establishment of a useful and reliable memory systems model, studies 
have shown that the hippocampus is involved in mnemonic processing, particularly in 
"declarative" tasks (Astur, Laughlin, Mamelak, Philpott, & Sutherland, 2002; Bohbot, 
Kalina, Stepankova, Spackova, Petrides, & Nadel, 1998; Smith & Milner, 1981; Squire, 
1992). 
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Amnesic patients. Human studies investigating the role of the hippocampus in 
memory processing have revolved around deficits exhibited by amnesic patients. Milner 
(1962) introduced findings that memory is dependent on the medial temporal lobe in the 
patient H.M.. The medial temporal lobe anatomically includes the hippocampus. When 
the medial temporal lobe was removed bilaterally in order to ameliorate epileptic 
symptoms, the patient H.M. displayed severe amnesia. H.M. displayed severe amnesia in 
his inability to form any new memories involving factual information. A similar study 
involving amnesic patients has been implicated in an attempt to integrate the role of the 
hippocampus in memory processing (Zola-Morgan, Squire, & Amaral, 1986). For 
example, in the case ofpatient R.B., the presence of a post-mortem examined bilateral 
lesion in the CAl region of the hippocampus is believed to be responsible for marked 
decreases in memory performance. Similarly, patients with bilateral lesions to the 
hippocampus have exhibited decreases in maze learning (Corkin, 1965). 
Functional magnetic resonance imaging. Functional magnetic resonance imaging 
(fMRI) studies have provided insight into the function of the hippocampus on declarative 
memory tasks by increasing visual acuity (Press, Amaral, & Squire, 1989). Imaging has 
shown shrinkage ofbrain areas (fimbria, dentate gyrus, hippocampus proper, and 
subiculum) within the hippocampus ofpatients suffering from memory deficits (Squire, 
1992). After examining symptoms associated with amnesic patients and fMRI studies, it 
is clear that the hippocampus is predominantly involved in declarative memory tasks. 
Hippocampus and memory: evidence from rat studies 
Declarative memory impairments seen in rats similarly emphasize the role of the 
hippocampus. Much of the research involving rats has utilized hippocampallesioning 
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techniques in order to produce reliable processing deficits (Aggleton et aI., 1986; Sloan, 
Dobrossy, & Dunnett, 2006; Squire, Clark, West, & Zola, 2001). As seen in human 
amnesic patients, bilaterallesions to the CAl region in the rat hippocampus have likewise 
produced memory dysfunction (Barnes, 1988; Sutherland & Rudy, 1989). 
Subsequent studies have shown the importance of the hippocampus in spatial 
memory tasks, thereby indicating the role ofworking memory (Bannennan, Yee, Good, 
Heupel, Iversen, & Rawlings, 1999; Cassel, Cassel, Galani, Kelche, Will, & Jarrad, 1998; 
Eichenbaum, 1997; Olton, Becker, & Handelmann, 1979). Lesions to the hippocampus 
have lead to severe deficits in processing spatial infonnation on working memory tasks 
(Aggleton et aI., 1986; Olton & Rawlings, 1982). Working memory in rats is often tested 
within the context of a delayed-dependency task, meaning that the longer the delay after 
presentation of items and before recall, the greater the impainnent on memory (Dunnett, 
1985). 
A novel test, the conditional delayed matching and non-matching to position task, 
has integrated aspects of the delayed-dependency task in order to show that hippocampal 
lesions positively weaken memory processing (Sloan et aI., 2006). Following a review of 
relevant rodent literature, it is apparent that the hippocampus is involved in memory 
processing on declarative tasks. 
Acetylcholine neurotransmission and memoryformation. 
It is clear that an interaction exists between multiple memory systems and the 
neurotransmitter ACh (Gold, 2004; Kesner, 1998; Whishaw, 1985; White & MacDonald, 
2002). Whether ACh modulates memory processing or processing modulates ACh 
release has been debated (Gold, 2003). However, as a means of identifying memory 
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activation within the hippocampus and other brain regions (e.g., amygdala, striatium, and 
hippocampus), ACh transmission has proven quite useful (Dutar et aI., 1995; Everitt & 
Robbins, 1997; Sarter & Bruno, 2000). The present study will focus only in ACh 
transmission within the hippocampus because the medial septum, the main source ofACh 
to the hippocampus, is the only region that will be lesioned. 
Acetylcholine production and transmission. ACh exists predominantly in the 
peripheral nervous system and brain tissue. It is synthesized within axon terminals from 
the precursors choline and acetyl coenzyme A (acetyl CoA) via a one-step reaction (see 
Figure 2). 
Once synthesized, ACh is stored for subsequent utilization in synaptic vesicles and 
released after the induction of an action potential. When the action potential stimulates 
the axon, an influx of calcium (Ca2+) ions into the terminal causes vesicles containing 
ACh to fuse with the outermost internal region of the terminal. After fusing, ACh 
neurotransmitters are released into the synaptic cleft where they bind reversibly with 
receptors on the post-synaptic dendritic membrane. Binding causes an influx of sodium 
(Na+) ions into the post-synaptic cell, resulting in propagation of the action potential. 
Following Na+ entry, receptor-bound ACh is immediately broken down by the enzyn1e 
acetylcholine esterase (AChE). 
17 Memory Deficits and Norepinephrine Agonist 
1 1 
--N~ 
/	 AX(jlllmninal 
MitDCbntldriQtl 
C#~ 
-Innow 
\tlsidcof ACfI -~-
~yol!f'(k cell mc:mmlll!lC .. / ACIlrcceptw 
AChE-DL! 
Figure 2. Cholinergic synapse. Acetylcholine is made in the axon terminal from acetyl coenzyme A (acetyl 
CoA) and choline, stored in vesicles, and released. When the action potential arrives at the terminal, closed 
calcium channels in the terminal are opened and Ca2+rushes into the terminal, triggering vesicles to fuse 
with the membrane and release ACh molecules into the synaptic cleft. ACh molecules attach to ACh 
receptors on the postsynaptic membrane and trigger the opening ofNa+ channels. ACh is immediately 
broken down at the receptors by acetylcholine esterase (AChE) into choline and acetate, which are taken 
back up by the terminal and reused (adapted from Julien, 2005). 
Detecting acetylcholine activity. One method of investigating ACh modulation in 
the hippocampus is by the use of cholinergic agonists and antagonists (Bartus, Dean, 
Beer, & Lippa, 1982; Coyle, Price, & Delong, 1983). These techniques make it possible 
to observe the effects of decreasing or increasing ACh levels during memory tasks. For 
example, cholinergic antagonists, such as scopolamine, have been shown to decrease 
ACh release when injected into the hippocampus, thereby impairing memory (Carli, 
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Luschi, & Samanin, 1997; Farr, Flood, & Morley, 2000; Gold, 2003; Lilliquist,
 
Burkhalter, Lobaugh, & Amsel, 1993; Ohno, Yamamoto, & Watanabe, 1994; Wallenstein
 
& Vago, 2001). In contrast, agonists, such as physostigmine, have been shown to
 
increase ACh release in the hippocampus, consequently enhancing memory (Mae1icke,
 
Schrattenholz, Samochocki, Radina, & Albuquerque, 2000; Nistri & Di Angelantonio,
 
2002). Collectively these findings indicate that obstructing ACh neurotransmission leads
 
to impairment, while stimulation of the cholinergic pathway increases memory
 
processing within the hippocampus (Chang & Gold, 2004).
 
Subsequent methods have been utilized to show that increasing ACh release in 
the hippocampus increases memory processing. Recently, assessing such increases in 
ACh in live and awake animals has been made possible due to novel advances in 
technology (e.g., tMRI, mircodialysis, HPLC). For example, a precursor to ACh 
synthesis, choline has been shown to increase in uptake within ACh neurons throughout 
memory tasks (Messier, Durkin, Mrabet, & Destrade, 1990). Additionally, glucose 
injection into the hippocampus increases ACh release during memory-dependent training 
tasks in the rat (Ragozzino, Wenk, & Gold, 1994; Ragozzino, Unick, & Gold, 1996; 
Ragozzino, Pal, Unick, Stefani, & Gold, 1998). Furthermore, pregnenotone, a 
neurosteriod, increases both ACh release in the hippocampus and performance on tasks 
of spatial memory (Darnaudery, Koehl, Piazza, Le Moal, & Mayo, 2000). 
Acetylcholine modulation. Increased ACh release has been observed in a number 
ofmemory related hippocampal-dependent tasks. For instance, Fadda and colleagues 
(1996) have observed increased ACh release during working memory tasks. ACh release 
has been shown to increase on tasks of visual discrimination (Yamamuro, Hori, Tanaka, 
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Iwano, & Nomura, 1995). The presentation of novel stimuli within a novel environment 
has triggered an increase in ACh transmission in the rat (Aloisi, Casamenti, Scali, Pepeu, 
& Carli, 1997; Inglis & Fibiger, 1995). Brain-region specific ACh release in the rat has 
also been observed during performance on a T-Maze task (Chang & Gold, 2003; 
McIntyre, Pal, Marriot, & Gold, 2003). Although tasks discussed above are associated 
with memory processing, the aim of each study may not have been to exclusively 
investigate such outcomes on memory. Nonetheless, these studies were useful in 
substantiating evidence for the hypothesis that increased ACh levels are correlated to an 
increase in memory processing. Further evidence supports the link between decreased 
ACh transmission and decreased memory processing following lesions to the medial 
septum. 
The medial septum: acetylcholine modulation and memory processing 
The septal-hippocampal (SH) projection of cholinergic neurons in the medial 
septum and vertical limb of the diagonal band (MSNDB) are believed to provide the 
main source of ACh to the hippocampus (Dutar et aI., 1995; Segal & Auerbach, 1997) 
(see Figure 3). The SH pathway originates within the basal forebrain, particularly the 
medial septum. The medial septum is divided into the medial septal nucleus and nucleus 
of the vertical and horizontal limbs of the diagonal band ofbroca (McKinney, Coyle, & 
Hendreen, 1983; Dutar et aI., 1995). 
There is much support for the hypothesis that a decrease in ACh is associated with 
decreased memory performance. For example, morphine injection into the intraseptal 
pathway in the hippocampus decreases ACh release and memory processing (Ragozzino 
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& Gold, 1995). Galanin, a neuropeptide, has been shown to decrease both ACh release 
and learning on spatial tasks in the rat (Ogren, Kehr, & Schott, 1996). 
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Figure 3. Representation of the cholinergic system in the rat brain. The central cholinergic neurons exhibit 
two basic organizational schemata: (1) local circuit cells (those that morphologically are arrayed wholly 
within the neural structure in which they are found) exemplified by the interneurons of the caudate-
putamen nucleus; (2) projection neurons (those that connect two or more different regions). Of the 
cholinergic projection neurons that interconnect central structures, the major subconstellation implemented 
in this study deals with the forebrain cholinergic complex composed of neurons in the medial septal 
nucleus (ms) and the nucleus basalis (bas) [circled in figure] and projecting to the entire nonstriatal 
telencephalon (adapted from Woolf, 1991). 
In the present experiment, the medial septal area has been chosen for lesion over 
other brain regions for several reasons. First, it has been shown through extensive 
histological analysis that the sole projection of acetylcholine to the hippocampus 
originates in the medial septum. Since a primary aim of the present study is to examine 
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the role of the cholinergic system within AD, it is only logical to lesion the medial 
septum. Second, lesioning the hippocampus directly reduces the ability of the present 
manipulation to generalize to human populations. This lack of generalization results 
from the observation that patients with AD possess an intact hippocampus. Lesioning the 
rat hippocampus directly would not maximally mimic AD within a human 
Effects ofmedial septum/vertical diagonal band lesions. Decreases in ACh 
resulting from lesions to the MSNDB have been associated with decreases in 
hippocampal-dependent memory impairment (Bartus et aI., 1982). For example, 
decreases in working memory have been found following lesion to the MSNDB (Decker, 
Radek, Majchrzak, & Anderson, 1992; Walsh, Herzog, Gandhi, Stackman, & Wiley, 
1996). 
Furthermore, memory-based place navigation task has displayed marked 
impairment following lesion to the MSNDB in the rat (Hagan, Salamone, Simpson, 
Iversen, & Morris, 1988). Similarly, spatial memory performance has decreased in rats 
following chemical lesion to the intraseptal pathway in the MSNDB (Janis, Glasier, 
Fulop, & Stein, 1998; Nilsson, Leanza, Rosenblad, Lappi, Wiley, & Bjoklund, 1992). 
Memory deficits resulting from lesions to the MSNDB produce strikingly similar 
learning and memory impairments as seen in damage to the hippocampus (Hagan et aI., 
1988; Decker et aI., 1992; Janis et aI., 1998). It is reasonable to conclude that learning 
and memory is most likely modulated by the interdependent functioning of ACh within 
both brain regions. 
A selective toxin for ACh neurons, 192 IgG-saporin, has been used to chemically 
lesion the MSNDB via direct injection. 192 IgG-saporin acts to eliminate ACh neurons 
Memory Deficits and Norepinephrine Agonist 22 
by joining saporin, the ribosome inactivating protein, with a monoclonal antibody to the 
p75 cholinergic nerve growth factor receptor (see figure 4). This activity decreases ACh 
3 
Figure 4. Action of the neurotoxin 192 IgG-saporin: (1) Monoclonal antibody obtained specific to the ACh 
cell type, (2) Inject saporin, which is lethal inside ACh cell, (3) Saporin binds to the monoclonal antibody, 
(4) Saporin-antiobody complex targets the p75 nerve growth factor recpetor, (5) The saporin-antibody-p75 
receptor compex is internalized into the ACh call, (6) The saporin-antiobody-p75 receptor complex enters 
the ACh cell completely, (7) The bond between saporin and the antibody-receptor complex is broken, 
releasing saporin, & (8) Saporin binds, inactivating the ACh ribosome: cell death. 
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transmission in the hippocampus and provides a neurochemical marker for measuring 
levels ofACh in the hippocampus (details: see Chang & Gold, 2004; Pottter, Gaughan, & 
Assouline, 1999). Numerous studies have shown that lesions to the rat MS result in 
decreases of acetylcholine esterase, choline acetyltransferase (ChAT), and ACh levels in 
the hippocampus (Lewis, Shute, & Silver, 1967; Oderfeld-Nowak, Nariewicz, Bialowas, 
Dabrowska, Wieraszko, & Gradkowska, 1974; Potemska, Gradkowska, & Oderfeld­
Nowak, 1975). This indicates that decreases in ACh levels lead to decreases in ChAT 
levels. 
The saporin lesion agent is ofparticular interest because it will be used in this 
investigation to lesion the rat MSNDB in an attempt to model the decreased levels of 
ACh as seen in Alzheimer's disease patients. In addition, 192 IgG-saporin is useful 
because it only targets ACh neurons, leaving all other neurons undamaged and functional. 
Since the MS/VDB projects to the hippocampus, lesioning the MSNDB has been shown 
to produce substantial deficits in memory processing within the hippocampus (Berger­
Sweeny, Steams, Murg, Floerke-Nashner, Lappi, & Baxter, 2001; Chang & Gold, 2003; 
Janis et aI., 1998; Nagle, Liberatore, Aombon, Pokala, Li, Pokala, & Johnson, 2002; 
Pokala, Libertore, Zambon, Nagle, Li, Witt-Enderby, & Johnson, 2002; Vale-Martinez, 
Baxter, & Eichenbaum, 2002). 
While 192 IgG-saporin lesions in the MS/VDB have produced memory deficits, 
presumably due to a loss ofChAT-positive neurons, numerous studies have not replicated 
such decreases in processing following the same lesion technique (Baxter, Bucci, Wiley, 
Gorman, & Gallagher, 1995; Baxter, Bucci, Sobel, Williams, Gorman, & Gallagher, 
1996; Baxter & Murg, 2002; Bizon, Han, Hudson, & Gallagher, 2003). Results from 
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these investigations have shown that 192 IgG-saporin does not decrease memory 
processing on certain memory tasks when injected in the MSNDB. Importantly, such 
evidence exists within observations of the same experiments that nearly all of the ChAT­
positive neurons in the MSNDB were eliminated. This seems to suggest that 192 IgG­
saporin lesions, while effective in decreasing ChAT-positive neurons, do not effectively 
decrease mnemonic processing. 
Gold (2003) offers several explanations for the negative findings associated with 
192 IgG-saporin as discussed above. Firstly, a threshold level ofACh neuronal loss 
might be necessary to produce marked memory impairments (Leanza, Nilsson, Wiley, & 
Bjorklund 1995 in Gold, 2003; Wrenn, Lappi, & Wiley, 1999). Secondly, 192 IgG­
lesions might not be a definitive measure, which would allow one to make the conclusion 
that ACh projection from the MSNDB to the hippocampus is a sufficient contributor to 
memory deficits as a single causal entity. Perhaps one domain ofmemory does not 
require stimulation of the intraseptal pathway. Investigating the effects of lesioning this 
projection would therefore yield no observed memory deficits. Thirdly, neuronal 
restructuring might compensate for the loss of ACh function (Crutcher & Davis, 1981; 
Decker & Mcgaugh, 1989; Olton, 1991). Perhaps sympathetic in-growth from alternative 
projections ofundamaged brain regions might increase ACh production and availability 
to the hippocampus. Certainly, if ACh is intensively involved in memory formation, the 
origin ofACh projection is irrelevant. 
Alzheimer's disease: decreased memory processing and acetylcholine levels 
Alzheimer's disease (AD) is the most widespread neurodegenerative disease 
affecting nearly two-thirds of all patients diagnosed with dementia (Nussbaum & Ellis, 
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2003). The general progressive characteristic ofAD accounts for irreversible losses of 
cholinergic neurons and synapses with the hippocampus (Coyle et aI., 1983; Davies & 
Maloney, 1976). Recognizable detection ofAD symptoms most often occurs after 60 
years of age, although rare diagnosable forms have also occurred before this age. 
Prevalence rates increase rapidly within normal aging populations, ranging from 1% 
among 65-69 years of age to 40-50% among 95 years of age with men accounting for 
slightly less cases per age bracket (Nussbaum & Ellis, 2003). Death usually results 
within 8-10 years following symptomatic onset. Decreases in memory processing, 
capacity, and learning capabilities seems to be the most prominent debilitating and 
maladaptive symptoms. Currently, a definitive diagnosis can only be made after post­
mortem brain autopsy. While the cause ofAD continues to remain a mystery, senile 
neuritic plaques and neurofibrillary tangles mark the diagnosable brain tissue (Yamada & 
Nabeshima,2000). Recently, similar impairments seen within the cholinergic 
neurotransmission system have been hypothesized to account for AD-type memory 
dysfunctions (Bartus et aI., 1982; Coyle et aI., 1983). 
The "cholinergic hypothesis". The "cholinergic hypothesis" has sought to 
account for memory deficits associated with Alzheimer's disease patients by considering 
the cholinergic system (Bartus et aI., 1982; Coyle et aI., 1983). Describing a correlation 
ofthis magnitude must consider three criteria elaborated by Bartus et aI. (1982): (i) very 
specific impairments must exist within the cholinergic system ofAD patients, 
substantially more severe when compared to deficits seen in a normal aging populace (ii) 
deliberate impairment of the cholinergic system in young subjects should produce deficits 
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similar to those impairments seen in an AD populace (iii) enhancement of the cholinergic 
system should decrease memory deficits similar to those seen in an AD populace. 
Many studies have shown reduced levels of ChAT and AChE in brains of AD 
patients as compared to a normal-aged sample (Bowen, Sims, Benton, Curzon, Davison, 
Neary, & Thomas, 1981; Giacobini, 2003; Kuhar, 1976). Giacobini (2003) found that 
AD patients exhibited decreased AChE levels by 60-80%. It is logical to hypothesize 
that decreases in AChE levels is a direct result of decreases in ACh neurons because 
AChE breaks down ACh within the synapse. These reductions indicate that decreased 
ACh levels might predominately contribute to those AD memory deficits observed 
(Bowen et aI., 1981; Winkler, ThaI, Gage, & Fisher, 1998). Particularly, decreased levels 
of ChAT have been observed in the basal forebrain, which contains the medial septum, in 
AD patients (Whitehouse, Price, Clark, Coyle, & DeLong, 1981; Whitehouse, Price, 
Struble, Clark, Coyle, & Delong, 1982). While normal aging is associated with decreases 
of cholinergic neurons in the basal forebrain these reductions are not nearly as great when 
compared to neuronal loss in AD patients (Bartus et aI., 1981). 
Deliberate impairments made to the cholinergic system in young human and rat 
subjects have produced memory deficits similar to those seen in AD subjects (Carli et aI., 
1997; Decker et aI., 1992; FaIT et aI., 2000; Gold, 2003; Hagan et aI., 1988; Lilliquist et 
aI., 1993; 0000 et aI., 1994; Thiel, 2003; Wallenstein & Vago, 2001; Walsh et aI., 1996). 
Much of the work dealing with cholinergic impairment within the hippocampus has been 
limited to the cholinergic antagonist scopolamine and medial septum lesions using 192 
IgG-saporin. Details regarding the magnitude of impairment necessary to produce AD­
type deficits using scopolamine and 192 IgG-saporin can be found above in the sections 
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titled "ACh neurotransmission and memory formation" and "the medial septum: ACh 
modulation and memory processing" respectively. 
Enhancement of the cholinergic system has conversely been shown to decrease 
memory deficits by decreasing AD-type impairments (Suzuki, Yamatoya, Sakai, 
Kataoka, Furushiro, & Kudo, 2001). One such method involves the use ofACh 
precursors. Upon injection into the brain, precursors become converted into choline, thus 
allowing for increased synthesis of ACh from choline and acetate. One such precursor, 
lecithin, is correlated to marked increases in performance on a Morris water maze task 
after administered orally to rats exhibiting AD-type deficits (Suzuki et aI., 2001). In 
addition, rats displaying AD-type memory deficits following scopolamine administration 
exhibited decreases in impairment after the delivery oflecithin (Fumshiro, Suzuki, 
Shishido, Sakai, Yamatoya, & Kudo, 1997). Similarly, rats subcutaneously administered 
the precursor, choline chloride, displayed increases in performance on the same Morris 
water maze task (Tees & Mohammadi, 1999). While ACh precursors have produced 
evidence for decreasing memory deficits, beneficial effects are extremely limited and 
lack effectiveness (Kumar et aI., 1998). 
Acetylcholine esterase inhibitors. Acetylcholine esterase inhibitors (AChE-I) 
have shown the most promise in ameliorating memory impairments in AD patients. This 
class ofpharmacological agents increases the availability of ACh, by preventing the 
hydrolysis ofACh by acetylcholinesterase, thereby increasing stimulation of ACh 
receptors, (Prickaert et aI., 2005; Rogers, 1998). Since ACh receptor activation in the 
HPC and MS has been shown to increase memory performance, AChE-Is have been 
utilized in the AD populace (Delagarza, 2003; Kumar, Durai, & lobe, 1998; Rogers, 
28 Memory Deficits and Norepinephrine Agonist 
1998). Presently, four AChE-Is have been approved by the Food and Drug 
Administration for use in AD: tacrine (Cognex), rivastigamine (Excelon), donepezil 
(Aricept), and galantamine (Reminyl). 
Several alarming issues have arisen since the introduction ofprescription AChE­
Is for AD treatment. One problem that exists is that inhibition of ACh hydrolysis 
produces serious side effects in AD patients. Many common side effects include nausea, 
anorexia, aggression, liver toxicity, and cardiovascular irregularities (Lazartigues, 
Freslon, Tellioglu, Brefel-Courbon, Pelat, Tran, Montastruc, & Rascol, 1998). Secondly, 
AChE-Is have exhibited low levels of efficacy in AD patients because these agents only 
moderately delay memory impairment (Doody, 2003). One study indicates that only 20% 
of AD patients will experience a one-year delay in full cognitive impairments (Tariot, 
Solomon, Morris, Kershaw, Lilienfeld, & Ding, 2000). Rat studies with AChE-Is show 
only modest improvements in cognitive deficits (for review see: Ohara, Fukaya, Tanaka, 
& Seno, 1997). Furthermore, AChE-Is do not cure or avert the onset ofAD. No single 
treatment for AD is capable of obtaining such results. As AD progresses and ACh 
neuronal levels continue to decrease, cholinergic AChE-I therapies decrease drastically in 
effectiveness (Lazartigues et aI., 1998; Mann, Yates, & Hawkes 1982). One reason 
cholinergic treatments are not more efficient in ameliorating deficits is that AD is not 
solely a cholinergic insufficiency. Being a very complex illness, AD is likely to induce 
impairments in multiple neurotransmitter pathways (D'Amato, Zweig, Whitehouse, 
Wenk, Singer, & Mayeux, 1987; Herrmann, Lanctot, & Khan, 2004). 
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Norepinephrine and Alzheimer's disease 
While degradation of the ACh pathway has been studied extensively, the NE 
transmitter pathway has been investigated less. Several studies indicate that decreases in 
NE neurotransmitter levels have been noted in AD patients (Bondareef et aI., 1981; 
Mann, Lincoln, Yates, Stamp, & Toper, 1980; Mann et aI., 1982). The NE system 
contains two projection orientations: (1) the ventral noradrenergic bundle, forming a main 
part of the lateral tegmental system and (2) the ascending dorsal noradrenergic bundle of 
the locus coeruleus system (see Figure 5). The dorsal bundle is of particular interest in 
the present manipulation because it projects directly into the hippocampus. 
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Figure 5. The noradrenergic system in the rat brain. Projections of the noradrenergic neurons are shown in 
a sagittal view. Clusters of cell bodies are shown as dots and are differentiated by the number prefixed by 
the letter A, according to the scheme ofDahlstron and Fuxe (adapted from Cotman & McGaugh, 1980). 
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Cell loss in the locus coeruleus (LC) has been noted in AD patients (Forno, 1978; 
Friedman, Adler, & Davis, 1999; Hoogendijk, Feenstra, Botterblom, Gilhuis, Sommer, & 
Kamphorst, et aI., 1999; Marcyniuk, Mann, & Yates, 1986). The LC is the predominant 
brain region that provides the main source ofNE to the HPC. While LC anatomy is 
beyond the scope of this paper it is useful to understand the projections of the LC. 
Locus coeruleus anatomy. The LC is the largest noradrenergic nucleus in the 
human and rat brain, containing approximately 15,000 NE neurons per hemisphere in 
humans and 1,600 neurons per hemisphere in rats (Coull, 1994; Foote, Bloom, & Aston­
Jones, 1983; Rogawski, 1985). It is located next to the fourth ventricle in the pontine 
region of the brainstem (see Figure 5). The LC innervates roughly every component of 
the telencephalon and diencephalon; most notably the hippocampus, neocortex, 
amygdala, septum, thalamus, and hypothalamus. The HPC obtains NE innervation 
entirely from the LC. The LC contains alpha (a) and beta (~) receptor types. The~­
receptor type is further divided into ~I, ~2, and ~3-receptor subtypes. ~-receptors have 
been isolated in the heart, spleen, bladder, and other major organs. The a-receptor type is 
divided into ala, alb, aid, a2a, a2b, and a2c-receptor subtypes. Areas ofhigh-affinity a2­
receptor binding includes the dentate gyrus ofthe hippocampus and the substantia nigra 
pars reticulata. 
Norepinephrine neuronal sprouting. Many studies have indicated that NE 
neuronal sprouting within the HPC occurs after lesion to the medial septum area 
(Crutcher & Davis, 1981; Crutcher & davis,1981; Madison & Davis, 1983). In fact, 
fibers projecting to the HPC from the LC pass through the MS (Loy, Milner, & Moore, 
1980). Considering the decrease in ACh neurons after MS lesion, NE axons within the 
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MS might trigger NE in-growth in compensation for decreased ACh MS projections. 
This hypothesis is supported by the observation that after a MS lesion, NE fibers within 
the HPC increase substantially in number (Crutcher & Davis, 1981; Madison & Davis, 
1983; Stenevi & Bjorklund, 1978). It might be the case that NE sympathetic fibers 
replace damaged ACh neurons, thereby compensating for ACh by increasing NE 
projection to the HPC. The compensation for ACh neurons could account for cholinergic 
denervarion ofthe HPC. For this to be a logical conclusion, post-synaptic NE stimulation 
must produce similar effects to those seen in post-synaptic cholinergic receptor 
stimulation. Results in support of this concept are few and must be studied in further 
detail. Based on extensive histological examinations, possible sites of interaction 
between the noadrenergic and cholinergic transmitter systems have been proposed (see 
Figure 6). 
The compilation of evidence presented above shows that NE and ACh 
neurotransmitter systems interact in the modulation ofmemory formation within the 
HPC. Decker and colleagues (1991) have presented anatomical details of such an 
interaction (see Figure 6). Results have been shown that blockade of either system 
produces memory impairments (Sirvio & MacDonald, 1999). Additionally, ACh and NE 
have been shown to modulate each other's release within the HPC (Azam & McIntosh, 
2006; Moroni, Tanganelli, Antonelli, Carla, Bianchi, & Beani, 1983). Furthermore, 
stimulation ofNE receptors in the MS produce increases of ACh in the HPC (Robinson, 
Cheney, & Costa, 1978). 
One study by Kruglikov (1982) provided further evidence that memory is 
modulated by NE and ACh collectively. Normal animals were given scopolamine and 
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exhibited decreases in memory on an avoidance task. Next, rats that had been 
administered the scopolamine were given a LC lesion. The combination of the LC lesion 
and scopolamine produced much larger impairments. Conclusively, pharmacological 
agents merely targeting the ACh system may be one reason cholinergic therapies within 
the AD populace are ineffective. 
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Figure 6. Hypothetical model of sites at which cholinergic and noradrenergic interactions might occur. 
Darker lines indicate norepinephrine projections while thin lines indicate acetylcholine projections. 
Norepinephrine agonists and Alzheimer's disease treatment 
Considering the nature oflearning and memory tasks, in which NE potentially 
interacts with the cholinergic system, NE agonists might be useful in reducing memory 
deficits observed within Alzheimer's patients. Several studies have indicated that alpha-2 
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receptor subtype adrenergic agonists improve memory on a variety of tasks (Amsten et 
al., 1988; Amsten & Goldman-Rakic, 1990; Amsten & Leslie, 1991; Amsten & Contant, 
1992; Amsten & Cai, 1993; Jakala, Riekkinen, Sirvio, Koivisto, Kejonen, & Vanhanen, 
1999; Rama, Linnankoski, Tanila, Pertovaara, & Carlson, 1996; Sirvio et al., 1991). One 
such agonist, Guanfacine, is particularly relevant because it will be administered in the 
present experiment to post-lesioned rats. 
Guanfacine has been shown to increase memory performance in numerous animal 
and human studies. For example, Guanfacine has been shown to improve delayed 
response performance in aged monkeys (Rama et al., 1996). In addition, low doses of 
Guanfacine have improved performance in aged rats on a spatial navigation task (Sirvio 
et al., 1991). Furthermore, Guanfacine has improved memory in aged monkeys on tasks 
involving the utilization of working memory (Amsten et al., 1988; Arsten & Cai, 1993). 
Guanfacine has shown similar effective results in humans, improving performance on 
working memory tasks (Jakala et al., 1999). 
Applied together, Guanfacine is an exciting novel pharmacological agent that be 
useful in the treatment of AD-type memory deficits. Studies involving the administration 
of Guanfacine after MS lesions on a socially transmitted food preference task are 
nonexistent. The present study will therefore allow for new conclusions and hypotheses 
to be made on the interaction between the NE and ACh transmitter pathways in memory. 
Quantification ofmemory: socially transmittedfood preference task 
In order to quantify memory performance a socially transmitted food preference 
task will be utilized. The STFP task is a nonspatia1 and spontaneous learning task. There 
are several benefits to using the STFP task in order to measure memory formation within 
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the current study. First, all food preferences are acquired in one training period with the 
demonstrated food, allowing for time points to be defined for acquisition and recall of the 
food preference. Second, food preferences, when transmitted socially, persist for several 
weeks, which will allow for sufficient testing time periods. Third, rats acquire the food 
preference through undemanding circumstances, which do not encompass spatial 
abilities, visual acuity, or exhausting locomotor activity; presence of which confounds 
interpretations of surgery-related variation in learning. Lastly, quantification of food 
preference memory is calculated as a preference for one of two foods, not total volume 
consumed during the task. This eliminates the possibility of surgery-related variations in 
motivation of the rats to eat as a universal characteristic of appetite. 
Existing literature indicates that observer rats exhibit a food preference after being 
exposed to a demonstrator rat that has recently consumed a flavored rat chow (Galef & 
Whiskin, 2003; Vale-Martinez, Baxer, & Eichenbaum, 2002). For example, an observer 
rat having been presented cocoa flavored chow via a demonstrator rate will exhibit 
preference to this flavored food for periods extending over one month (Clark, Broadbent, 
Zola, & Squire, 2002). This indicates that the rat has formed a declarative memory for 
coco-flavored chow. In addition, lesions administered prior to training have been shown 
to impair long-term memory formation and lesions administered after training have 
produced temporally graded retrograde amnesia for the STFP task. (Wincour, 1990; 
Wincour, McDonald, & Moscovitch, 2001; Clark et aI., 2002). 
Studies have shown increases in CREB phosphorylation and c-Fos expression in 
the hippocampus during a STFP task (Countryman & Gold, in press; Countryman, 
Orlowski, Brightwell, Oskowitz, & Colombo, 2005). It is also known that CREB 
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phosphorylation and c-Fos expression are both paramount in long-term memory 
formation (Brightwell, Smith, Countryman, Neve, & Colombo, 2005; Countryman, 
Kaban, & Colombo, 2005). Consequently, increases in either CREB or c-Fos can be used 
as a marker for long-term memory processing. This is very significant evidence 
indicating that the STFP task can be used to quantify declarative memory formation. 
Explanation of the STFP task used in this experiment can be found under the methods 
section. 
Summary and implications for the present study 
After a review of the literature it is clear that mnemonic processing requires the 
integration ofmultiple memory systems. The hippocampus is extensively involved in 
declarative memory tasks. The neurotransmitter acetylcholine has been shown to 
facilitate memory formation within the hippocampus. The medial septum is anatomically 
connected to the hippocampus and is the main source of acetylcholine to the 
hippocampus. Reductions in acetylcholine levels within the hippocampus and medial 
septum have been observed in Alzheimer's disease patients. Reductions in levels of the 
norepinephrine neurotransmitter have been associated with Alzheimer's disease. 
Norepinephrine sympathetic in-growth within the hippocampus has been observed 
following lesion to the medial septum, suggesting that norepinephrine and acetylcholine 
are modulated by one another. Norepinephrine agonists, particularly the alpha-2 
noradrenergic agonist Guanfacine, have shown to increase performance on a number of 
memory-related tasks in aged animals and humans. Until recently Guanfacine has been 
implicated in the treatment of AD-type memory deficits. However, no studies have 
investigated the effect of Guanfacine after a chemical lesion to the medial septum on a 
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socially transmitted food preference task. Therefore, the present study will measure the 
effects that Guanfacine has on memory processing of a socially transmitted food 
preference task following chemical lesion to the medial septum in the rat brain. 
Methods 
Subjects 
Thirty Long-Evans male rats (purchased from Harlan), at first weighing 250 g, 
served as both as demonstrator (d) (n=20) and observer (0) (n=IO) rats throughout the 
course ofthe experiment. Rats were maintained on a 12 h light-dark cycle in a humidity 
and temperature-controlled (approx. room temp.) environment. Over the course of the 
experiment, d and o-rats were pair-housed in 42 x 24 x 27 cm plastic bottom cages. 
Food and water were available ad libitum except during the 5 days before and after 
each training session. During this time, rats were placed on a 22 h food deprivation 
schedule with ad libitum water. Rats were housed and handled according to the Guide 
for the Care and Use ofLaboratory Animals (National Academy Press, Washington, 
D.C., 1996) and Illinois Wesleyan University IACUC. 
Surgery 
Surgeries of o-rats were done in the morning or afternoon hours. In the case of 
morning surgeries, food pellets were removed from the cage the night before surgery to 
increase the effectiveness ofthe anesthesia. In the case of afternoon surgeries, food was 
detracted from the cage in the morning of surgery to increase the effectiveness of the 
anesthesia. All anesthetics were injected into the abdomen of o-rats. Surgeries required 
that o-rats be administered approximately 0.3 ml/kg ketamine/xylazine anesthetic 
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solution, containing 8 mg ofketamine and 1.2 mg xylazine, under aseptic conditions. 
Supplemental injections of pure ketamine solution were injected if animals exhibited 
corneal, hindlimb, tail reflexes, excessive whisker movement or rapid respiratory o-rates. 
Body temperature was regulated and maintained over the course of the procedure using 
heating pads, in order to protect against heat loss. Instruments were autoclaved before 
surgery. Prior to surgery, o-rats were handled for approximately 5 separate times for five 
minutes each. 
During operations, o-rats received stereotaxic surgery, in which the medial 
septal/vertical diagonal band (MSNDB) was lesioned with 192-IgG-saporin. Once 
anesthetized and secured, o-rat scalps were cleaned with betadine scrub. A midline 
incision exposed the skull and the skull surface was leveled along the bregma-lambda 
axis. Sterile, autoclaved cotton-tip applicators were utilized while removing blood and 
debris. Following the incision, surgical clips were attached to the faschia, expanding the 
opening to the skull. 
The MSNDB surgery required that two holes be drilled in the skull at the 
stereotaxic coordinates AP +0.4 and ML ±1.0 mm from Bregma (Paxinos & Watson, 
1998 in Vale-Matinez et aI., 2002). Chemical lesions were made using a microinjector 
and a 28-gauge needle on a Hamilton syringe. The syringe was loaded with 0.15 ~g/~l of 
192 IgG-saporin (Sigma-Aldrich, St. Louis, MO) in sterile phosphate-buffered saline to 
be used with lesion o-rats or with sterile phosphate-buffered saline to be used with 
control o-rats. Saporin injections were made at depths DV -7.8 and -7.0 mm from the 
skull surface (see Figure 7 for infusion coordinates). 192-IgG-saporin/saline solutions 
were distributed at a rate of 0.05 ~l /min to a total volume 0.3 ~l at each of the DV -7.8 
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mm sites. Another 0.2 J..lI injection of solution was distributed at each of the DV -7.0 mm 
sites at a rate of 0.05 J..lI Imin. The needle remained stationary for 9 min following each 
0.3-J..lI injection and for 6 min following each 0.2 J..lI injection, thereby ensuring that the 
solution did not diffuse into the track of the needle. Bone wax was spread over the holes 
to ensure closure on drill sites. 
Figure 7. Injection coordinates for saporin infusion into the medial septum. Arrows indicate injection 
syringes. Cross hashes indicate coordinates of injection; anterior posterior ± O.4mm, medial lateral ± 
l.Omm, and dorsal ventral-7.8mm and -7.0mm. 
Three staples were used to close the skin. O-rats received injections of 0.2 mg/kg 
Rimadyl in order to minimize pain. After surgery, o-rats were placed into cages and 
returned to normal ad libitum food schedule. Animal body weight, locomotor action, and 
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posture were monitored for one full week following surgery. During this time, o-rats 
were handled daily for 3 min per day over the last five days of recovery. Animals were 
allowed to recuperate for one week before task testing, being handled 3 min per day for 5 
days. Two rat did not survive surgery and an additional eight rats did not recover from 
surgery. After all surgeries were completed group size for saporin lesioned rats was 7 
rats and there were 4 sham lesion rats. 
Pharmacological administration 
a-rats were administered a single dose of guanfacine (approximately 0.3 mL) 
(Sigma-Aldrich, St. Louis, MO) following post-lesion testing (see post-lesion group 
section), in order to determine the effects this pharmacological agent has on mnemonic 
processing. Guanfacine is a specific alpha-2 agonist, targeting receptors in the locus 
coeruleus (LC) brain region. Guanfacine was administered systemically, into the 
abdomen, in a single dose. Prior to administration, 10 mg guanfacine was diluted with 80 
mL saline. 
Behavioral procedure 
The behavioral procedure utilized a repeated measures design, consisting of a 
socially transmitted food preference (STFP) task, was used in order to assess non-spatial 
hippocampal-dependent memory in the o-rats. Behavioral procedures were similar to 
those utilized by Countryman, Orlowski, et al. (2005). Upon arrival in the lab, d and 0­
rats were allowed to habituate to surroundings for one-week. Following habituation, d 
and o-rats were handled for 5 min each day for 5 days and placed on a 22 h food 
deprivation schedule. Both d and o-rats underwent the same STFP task except with 
different food pairings, as described below in the pre-lesion group, post-lesion group, and 
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post-drug administration group sections. During the STFP task, d and o-rats were 
situated in opposite sides of an approximately 42 x 24 x 27 cm plastic bottom interaction 
cage. The cage was equipped with com cob bedding and a wire screen that was placed in 
the middle of the apparatus. Following training, d-rats and o-rats were returned to home 
cages. Five days after training, o-rats were tested for food preference in a novel room. 
Details ofthe STFP task are provided below because minor differences in the task pertain 
to each food preference-training group. 
The food preference test took place in a 42 cm 24 cm 27 cm plastic bottom cage. 
Two food cups were attached to opposite ends of the cage. Cups contained 
approximately 15 g each of separate flavored rat chow (cinnamon and coca; thyme and 
turmeric; marjoram and coriander, cumin and oregano, ginger and nutmeg), see Table 1. 
a-rats were placed so that they were straddling a ledge in the center of the cage facing a 
wall. The ledge prevented food from mixing. a-rats were permitted to eat from the food 
cups for one-hour with water available for the entire hour. The amount of the remaining 
food was weighed 2-days following the end of the one-hour feeding period to ensure 
dryness. The amount of each flavored food, which was consumed during the food 
preference task, was calculated according to the following criteria: (1) (Demonstrated 
Food 1 offered - Demonstrated food 1 remaining) + (Novel food 2 offered - Novel food 
2 remaining) = Total Food Consumed; (2) [Demonstrated Food Consumed (g)/Total Food 
Consumed (g)] x 100 = Percentage of Demonstrated Food Consumed. 
Pre-lesion assessment offood preference 
The pre-lesion assessment of food preference was used to determine a baseline of 
mnemonic processing on a socially transmitted food preference task. The pre-lesion 
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group contained 20 rats. Twenty-four hours prior to training, d-rats and a-rats were 
placed into interaction cages and food deprived for 22 hrs. For training, d-rats were taken 
from the interaction apparatus and placed into an isolated room. In this location, d-rats 
were permitted to eat for 30 min from approximately 109 of flavored rat chow. Rat 
chow was mixed in with specific flavors, in accordance with a food pair chart (see Table 
1). D-rats were permitted to drink water whenever food was present. After 30 min had 
passed, d-rats were taken back to the interaction cage and allowed to interact with a-rats 
for 30 min through the wire-mesh divider in a training/learning session. Directly 
following the 30 min interaction period, d-rats and a-rats were returned to home cages 
and fed unflavored rat chow. After 5 days in home cages, a-rats were taken to a novel 
room and tested for food preference. The food preference task adhered to the guidelines 
listed in the behavioral procedure section. Following food preference testing, d and 0­
rats were returned and given food and water ad libitum. 
Post-lesion group assessment offoodpreference 
The post-lesion assessment of food preference was used to determine the effects 
that a 192 IgG-saporin medial septal (MS) lesion had on mnemonic processing. The 10 
surviving a-rats (3 sham and 7 saporin lesioned) were handled 5 min each day and placed 
on a 22 h food deprivation schedule for 5 days prior to the behavioral test. O-rats were 
then moved into interaction cages for 24 hrs before training begins. After 24 hrs, a-rats 
were tested on the same STFP task and tested for food preference, according to the 
procedure described in the pre-lesion section, except using a different food pair (see 
Table 1 for food pairs). Following testing for food preference, a-rats were returned to 
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their home cages for 1 week, while being monitored on a 22 h food deprivation schedule, 
until the post-drug administration assessment of food preference. 
FOOD A FOODB 
PAIRl Cinnamon (1 %) Cocoa (1%) 
PAIR 2 Marjoram (1 %) Coriander (1 %) 
PAIR 3 Nutmeg (0.8%) Ginger (1 %) 
PAIR 4 Thyme (2%) Turmeric (1 %) 
PAIRS Oregano (1 %) Cumin (1%) 
Table 1. Food pairs. Representation offood used throughout the STFP task. If FOOD A demonstrated to 
d-rats, then o-rats presented both FOOD A and FOOD B during testing of preference. Demonstrated food 
was counterbalanced within food pair groups in order to ensure that novel food was presented during each 
STFP trial period. 
Post-drug administration assessment offood preference 
The post-lesion drug administration assessment of food preference was used in 
order to determine the effects that guanfacine had on mnemonic processing following a 
chemical lesion to the MS/VDB. The same 11 o-rats were administered guanfacine 30 
min prior to training in the dose according to the protocol described in the 
pharmacological administration section described above. Following administration, 0­
rats were tested on the same STFP task and for food preference, according to the 
procedure described in the pre-lesion section, except using a different food pair. 
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Histology and immunohistochemistry 
Following behavioral testing, o-rats received an overdose ofketamine/xylazine. 
Each subject was prepared for transcardial perfusion with a solution containing 0.9% 
saline and then 4% buffered paraformaldehyde. Following fixation, brains were removed 
and placed in a 20% sucrose solution. Brains were sectioned at 50Jlm with a Cryocut 
1800 (Reichert-lung) cryostat. Individual brain sections were collected in a 
cryopreservative until staining for choline acetyltransferase (ChAT). 
A modification ofthe staining procedures used by Chang and Gold (2004) and 
Countryman, Orlowski, et aI., (2005) was used to identify ChAT positive cells in the 
medial septum (MS). MS sections were washed 4 consecutive times for 10 min each in 
0.05M phosphate buffer solution (PBS). Following washing, sections were blocked for 
15 min in a solution containing 1% normal goat serum (NGS), 1% H202, and 0.4% TX in 
0.05 M PBS. Next, sections were washed for 10 min in 2% NGS and 0.2% TX in 0.05M 
PBS. Free-floating sections were incubated in small plastic wells at room temperature for 
48 hrs in a solution containing anti-ChAT rabbit primary polycolonal antibody (1: 100; 
Santa Cruz), 1% NGS, 0.2% TX in PBS. Sections were then washed 4 times for 12 min 
each in 0.05M PBS. Following washing, sections were incubated for 1 hr in a solution 
containing the biotinylated goat anti-rabbit secondary antibody (1 :400; Santa Cruz), 1% 
NGS, 0.4% TX in PBS. Sections were washed 3 times for 5 min each in 0.05M PBS. 
Following washing, sections were processed with avidin-biotinylated horseradish 
peroxidase complex (ABC Elite Kit, Vector Laboratories), 0.2% TX in PBS for 45 min. 
Sections were washed 4 times for 15 min each in 0.05M PBS. Next, sections were 
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visualized using diaminobenzidine (DAB Substrate Kit, Vector Laboratories) for 3 
minutes. Following incubation, sections were washed 3 times for 8 min each in O.OIM 
PBS. After washing, sections were mounted, set to dry, and protected with cover slips. 
ChAT stained tissue sections were imaged using a Nikon Y-FL Eclipse E600, 
Nikon Digital Sight DS-SM camera interfaced with an Intel Pentium 4-PC computer. 
ChAT positive cells in the medial septum were quantified using Scion Image, a pc 
equivalent program to NIH Image. Cells were identified and counted using protocols 
previously published (Countryman, Orlowski, et aI., 2005; Countryman, Kaban, et aI., 
2005). 
Results 
Preliminary comments. 
Following surgical lesion, subjects within the "post-lesion" group and "post­
lesion plus guanfacine" group displayed a significant decrease in total average food 
consumed, measured in grams. 
Subjects within the present manipulation exhibited a statistically significant 
formation of a food preference when compared to chance prior to saporin lesion and 
following guanfacine administration (after lesion) on the STFP task. In contrast, subjects 
did not exhibit a statistically significant memory formation of food preference following 
lesion. Furthermore, following lesion, subjects exhibited a statistically significant 
decrease in memory formation when compared to pre-lesion subjects on the STFP task. 
In contrast, subjects administered guanfacine (following lesion) did not exhibit a 
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statistically significant increase in memory formation when compared to post-lesion 
subjects on the STFP. 
Histological analysis revealed a trend toward significance between decreases in 
the number of ChAT-positive cells within the "sham" group and the number of ChAT­
positive cells within the saporin-administered group. Further analysis revealed a trend 
toward significance between increases in memory formation within the guanfacine­
treated group (following lesion) and increases in the number ofChAT-positive cells. 
Behavioralperformance: socially transmittedfood preference task. 
A repeated measures analysis of variance (rm-ANOVA) was performed to 
examine differences in total food consumed at each of the three tests time points (pre­
lesion, post-lesion, and post-lesion + guanfacine). A significant difference in total food 
consumption across the test time points was found, F(2,14) = 5.57,p < 0.05. In order to 
determine statistical significance between specific test time point groups, Fisher's post­
hoc test was performed. This statistical test revealed that pre-lesion rats consumed 
significantly more food when compared to the post-lesion average total grams offood 
consumed (p < .05). Similarly, pre-lesion rats consumed significantly more total food 
when compared to average total grams of food consumed post-lesion + guanfacine (see 
Figure 8). 
Next, a rm-ANOVA was performed to determine differences in the percentage of 
demonstrated food consumed at each of the three test time points (pre-lesion, post-lesion, 
and post-lesion + guanfacine). No significant difference between the percentages of 
demonstrated food consumed as a function of test time points was found, F(2,1O) = 3.08, 
p = 0.09 (see Figure 9). However, due to an a priori hypothesis that the percentage of 
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Figure 8. Total food consumed (grams) (mean ±s.e.m.) plotted as a function of test point time. Rats ate 
significantly less food at test after lesions to the medial septum were performed. PRE-L, pre-lesion; POST­
L, post-lesion; post-L + GUAN, post-lesion + guanfacine. *p < 0.05. 
demonstrated food consumed would decrease following 192 IgG-saporin administration 
and increase following guanfacine administration, Fisher's post-hoc test was performed. 
This statistical test revealed a significant decrease in the percentage of demonstrated food 
consumed from the pre-lesion to the post-lesion time point,p < 0.05. 
Furthermore, t-tests revealed that "PRE-L" [t(29) = 8.36,p < 0.05] and "POST-L 
+ GUAN" [t(lO) = 2.36,p < 0.05] groups consumed statistically more of the 
demonstrated food than the 50% chance level. When compared to chance, the "POST-L" 
group did not consume statistically more ofthe demonstrated food [t(10) = 1.75,p = 
0.11] (see Figure 9). 
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Figure 9. Percentage of demonstrated food consumed (mean ± s.e.m.) plotted as a function of test time 
points. Dotted horizontal line equivalent to chance (50%). *P < 0.05. 
Immunocytochemistry (ICC). 
In order to examine the neurotoxic effects of saporin, ChAT positive cells located 
within the medial septum were quantified using microscopic digital photo analysis. An 
illustrative representation of digital pictures taken in order to quantify ChAT positive 
cells is displayed in Figure 10. Analysis indicated the absence of a significant decrease in 
ChAT positive cells when considered as a function of treatment (sham vs saporin lesion), 
F (1,8) = 3.31,p = 0.10. While not significant, a considerable decrease in ChAT positive 
cells was apparent following administration of saporin (see Figure 11). In order to 
examine effect size, eta squared was calculated. Eta squared represents the proportion of 
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variance of the dependent variable that is explained by the independent variable. Eta sq = 
0.29. 
SHAM SAPORIN 
Figure 10. Representative images ofa brain infused with saline, sham operated (left column) and a brain 
infused with IgG-saporin (right column). Notice the lighter staining and decrease in number ofChAT 
positive cells. 
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Figure II. Number of ChAT positive cells (mean ± s.e.m.) plotted as a function of sham and saporin 
treatment, F (1,8) = 3.31, p = 0.10. 
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A decrease in ChAT cell count was expected to reveal a positive correlation with 
memory performance. Therefore, a correlation was computed in order to determine if a 
relationship existed between ChAT positive cells and post-lesion percentage of total 
demonstrated food consumed. Analysis revealed the absence of correlation between the 
number of ChAT positive cells within the medial septum and the post-lesion percentage 
of demonstrated food consumed, r = -0.20,P = 0.657. 
However, following further statistical analysis, a trend toward significance was 
revealed when considering the number of ChAT positive cells plotted as a function of 
total demonstrated food consumed in respect to the post-lesion + guanfacine time point, r 
= .63, p = 0.12 (see Figure 12). Power analysis with power level set at 0.80 and r = .63 
indicated that n = 17 would be necessary for a significant correlation. 
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Figure 12. Number of ChAT positive cells plotted as a function of post-lesion + guanfacine percentage of 
total demonstrated food consumed, p = 0.12. Computation of a trendline indicates a trend toward a 
significant correlation. 
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Discussion 
Administration of the cholinergic lesioning agent 192 IgG-saporin into the rat 
medial septum was utilized in the present study in order to investigate changes on a 
hippocampal memory-processing socially transmitted food preference task. Therefore, 
reductions in performance on the STFP task were expected following microinfusion of 
saporin. Following saporin infusion, systemic injection ofthe norepinephrine agonist 
guanfacine into the rat was employed in order to examine changes on the same STFP 
task. Guanfacine administration was expected to increase memory performance by 
compensating for decreased acetylcholine levels within the hippocampus. 
Behavioral effects of192 IgG-saporin 
Subjects were trained to acquire a STFP and tested for memory 5 days later. 
Since the task is hippocampus-sensitive and such processing has been shown to rely on 
ACh transmission, reductions in medial septum ACh levels were expected to lead to 
decreased behavioral performance. Performance on the STFP task in the present study 
significantly decreased following the administration of saporin. Such decreases in 
processing on the STFP task are quantified by calculating the percentage of demonstrated 
food consumed. This value refers to the amount ofmemory for the demonstrated food 
the rat population displayed (see method section for detailed STFP procedure). 
Observers in the "pre-lesion" group consumed on average 77% of the 
demonstrated food. This value is logical because transmission of acetylcholine within the 
hippocampus is assumed to be unaltered at this time point. It is important to note that 
acetylcholine neurotransmission is positively correlated with memory processing. 
Furthermore, the existence of such a high percentage indicates that memory formation of 
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the demonstrated food did in fact occur and that the long-term memory trace is 
maintained for periods extending beyond 5 days. Results ofthis nature are congruent 
with previous research on a STFP task indicating the persistence of the memory trace at 
long delays (Clark et aI., 2002, Countryman, Kaban, et aI., 2005). Vale-Martinez et aI. 
(2002) indicates similar findings that control subjects consumed on average 85% of 
demonstrated food during the STFP task when tested for preference 5 days following 
interaction with demonstrators. 
It is important to note that memory for the food preference was assessed after 5 
days for several reasons in the present study. First, previous research indicates that 
memory of a food preference can last for periods extending one month following 
demonstration (Clark et aI., 2002). This persistence ofmemory is relevant to the present 
study in that it validates the amount of time between demonstration and assessment of 
preference. If subjects display memory over a one-month period, certainly memory will 
be displayed after a 5-day period. 
Secondly, research indicates that aged animals begin to display decreases in 
memory for food preference by 72 hours on the STFP task (Countryman & Gold, in 
press). The same data indicate that by one week over 50% of aged rats are unable to 
maintain a memory for the demonstrated food. This information is applicable to the 
present study due to the lapse of time that passes before the onset of forgetting. If aged 
rats maintain memory for a socially transmitted food preference for up to 72-hrs, then the 
test for memory deficits due to lesions of the medial septum should be beyond this time 
point. Also, Vale-Martinez and colleagues (2002) have demonstrated that memory 
deficits for this task following IgG-Saporin lesions are apparent after 5 days. Even more 
52 Memory Deficits and Norepinephrine Agonist 
relevant is the fact that subjects in the present manipulation are assumed to represent the 
effects of aging - decreased cholinergic cells as a result of chemical lesion. 
Consequently, based on previous research, it is not surprising that subjects displayed 
memory for food preference following a 5-day period. 
Observers in the post-lesion group consumed on average 56% of the demonstrated 
food; just 6% above chance. Similarly, this value is consistent with the notion that 
decreases in acetylcholine neurotransmission, as a result of saporin administration, are 
responsible for decreases in memory formation of the demonstrated food. Vale-Martinez 
et al. (2002) present results that are consistent with the current findings of decreased 
processing following saporin infusion. Specifically, following administration of saporin 
into the medial septum/vertical diagonal band of Broca, percentage of total demonstrated 
food consumed by observers, when tested for food preference after 5 days of interaction 
with demonstrator, decreased by 45% when compared to pre-lesion percentages of total 
demonstrated food consumed. 
Furthermore, the lack of a significant value ofpercentage of demonstrated food 
consumed above chance when considering the post-lesion group is indicative of an 
absence of long-term memory formation. This conclusion is expected because saporin 
has been shown to decrease acetylcholine levels in the hippocampus when injected into 
the medial septum, thereby decreasing memory function (Gold, 2004). Berger-Sweeney 
et al. (2001) indicate similar decreases in swim Morris water maze performance 
following saporin lesion; a task applied in order to examine memory effects. 
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Surgery effects 
Surgery was performed in order to infuse saporin (via an automated microinfusion 
device) directly into the medial septal brain region (see methods section for detailed 
procedure). Following surgical procedures, "post-lesion" and "post-lesion plus 
guanfacine" administered subjects exhibited significant decreases in total average food 
consumed per test point, measured in grams. Findings of this nature are congruent with 
previous literature, which indicate that subjects having undergone surgery consume less 
total food on average as a side effect of surgical methods (Brightwell, et al., 2005; 
Countryman, Kaban, et al., 2005). Therefore, significant decreases in total average food 
consumed per STFP trial are not generally alarming and do not affect quantification 
measures ofmemory formation within this paradigm. 
Behavioral effects ofguanfacine 
Guanfacine is an alpha-2 norepinephrine agonist known to increase memory 
processing following administration in healthy human populations and aged non-human 
primates (Amsten et al., 1988; Amsten & Cai, 1993; Jakala et al., 1999). Therefore, 
increases in memory formation following training on the STFP task subsequent to saporin 
injection were hypothesized. Subjects in the present study did not exhibit a significant 
increase in memory formation on the STFP task from the "post-lesion" time test point to 
the "post-lesion plus guanfacine" test time point. This means that subjects in the 
guanfacine treatment group did not consume significantly more food when compared to 
subjects in the post-lesion group. 
However, rats in the post-lesion plus guanfacine treatment group did exhibit a 
significant increase above chance in the percentage of demonstrated food consumed. 
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Guanfacine treatment group rats exhibited a 63% demonstrated food consumed value; 
13% above chance. This means that guanfacine-treated subjects did consume 
significantly more demonstrated food within the "post-lesion plus guanfacine" STFP task 
test time point. 
Theoretical considerations: noradrenergic sympathetic sprouting. Previous 
literature indicates that administration of guanfacine (an alpha-2 adrenergic agonist) in 
the absence of a cholinergic lesion has led to increases in memory performance in aged 
monkeys and human populations (Amsten et aI., 1988; Arsten & Cai, 1993; lakala et aI., 
1999). In addition, Sirvio et aI. (1991) found increases in performance on a spatial 
navigation task within a rat population following guanfacine administration. 
Collectively, guanfacine seems to improve memory performance, at least partly among 
aged animal subjects. Consider aged animals, which consistently exhibit decreased levels 
ofACh within the hippocampus. It might be the case that increased stimulation of alpha­
2 adrenergic receptors, which project to the hippocampus, could improve memory 
formation in the presence ofdecreased ACh neurons. 
Of interest, following lesion to the cholinergic system, multiple studies have 
indicated sympathetic noradrenergic sprouting into the hippocampus (Crutcher & Davis, 
1981; Harrell et aI., 2001; Harrell et aI., 2005; Madison & Davis, 1982). Increased 
noradrenergic axonal sprouting might be a reasonable compensatory mechanism in 
response to ACh loss. This is logical to assume due to the fact that norepinephrine 
receptor stimulation in the absence of ACh loss already has been shown to stimulate 
increases in memory performance (Arnsten et aI., 1988; Arsten & Cai, 1993; lakala et aI., 
1999). It is plausible to conclude that stimulation of alpha-2 adrenergic receptors within 
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the locus coeruleus (the primary brain region, which projects NE to the hippocampus) by 
guanfacine may have increased delivery ofNE to the hippocampus at a greater rate due to 
increased NE sprouting. The increase in delivery ofNE to hippocampus following 
guanfacine administation may have compensated for decreases in ACh. Such 
compensation, therefore, may have led to the significant increases in values of 
percentages of total average demonstrated food consumed, indicative of increased 
memory performance. 
One important implication to consider when taking into account NE axonal 
sprouting is the time window immediately following the saporin lesion and the initial 
administration of guanfacine. One study by Harrell et al. (2001) indicated that a 
minimum of 8 weeks must pass following saporin infusion in order to visualize NE 
ingrowth via histofluoresence. In the present study, guanfacine injection took place only 
3 weeks following saporin administration. This is certainly an impetus in concluding that 
increased NE delivery via increased NE sprouting to the hippocampus actually occurred. 
It might be the case that NE axonal ingrowth did not commence prior to guanfacine 
injection. While considering this limitation in current methodology, it is important to 
recognize that studies indicating a minimum amount of time passage before NE ingrowth 
following saporin lesions to the MS are few and far between. In the present study, NE 
fiber ingrowth was not quantified, therefore conclusions gathered on the issue rely solely 
on the interpretation ofbehavioral and histological data. 
Immunohistochemistry: analysis ofsaporin within the medial septum 
In the present study, the relation between the number of choline acetyltransferase 
(ChAT) positive cells within the medial septum and memory performance was 
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investigated. ChAT is a good quantitative measure of acetylcholine neurons within tissue 
locales because ChAT is the enzyme that catalyzes the synthesis of acetylcholine. 
Therefore, high numbers of ChAT positive cells within the medial septum are indicative 
of large numbers of acetylcholine neurons. 
Since decreases in acetylcholine neurons have been correlated with decreases on 
memory-related tasks, it was necessary in the present study to perform similar 
histological analysis. Comparable studies that manipulated the medial septal area with 
saporin indicate greater reductions (approximately 60-70%) in ChAT-positive cells than 
the present manipulation (Berger-Sweeney et ai., 2001; Leanza et ai., 1995). The current 
analysis produced approximately a 35-40% reduction in ChAT-positive cells. Incomplete 
lesion to the medial septum with saporin is likely to have left intact a higher number of 
ChAT-positive cells and thus the lack of a significant reduction from the sham to saporin 
treatment group. This lack of a significant reduction in ChAT-positive cells is not 
entirely important due to the presence of a large effect size between the sham and saporin 
groups. Increasing the number of infusion sites of saporin within the medial septum will 
likely produce larger decreases in ChAT-positive cell bodies. 
In addition, statistical analysis of the data indicates the absence of a significant 
correlation between the number of ChAT positive cells and percentage of total 
demonstrated food consumed from the post-lesion group. Lack of a significant value 
indicates that memory performance did not necessarily rely on a certain number of 
acetylcholine neurons. That is, decreases in the number of acetylcholine neurons were 
not coupled with decreases in memory processing. This observation is not particularly 
surprising as extensive previous research analyzing correlations between cell counts and 
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memory performance has failed to present any significant values (Countryman, Orlowski, 
et al., 2005; Countryman, Kaban, et al., 2005; Countryman & Gold, in press). 
Not expectantly, on a purely statistical level, the present histological analysis is in 
direct conflict with performance on the behavioral STFP task. Data indicated that 
decreases in memory processing on the STFP task occurred following saporin lesion. 
Statistically, this decrease in performance should have been correlated with decreases in 
ChAT positive cell numbers. One explanation for the lack of significance relates directly 
to small control and manipulation group numbers (n=3 and n=7, respectively). Low 
numbers of subjects within these groups led to large values of standard error within such 
groups. It is very plausible that increasing the number of subjects within each group will 
be advantageous in reaching a statistically significant value. 
Contrary to the above findings, further analysis of data revealed a trend toward 
significance when considering the amount ofChAT positive cells plotted as a function of 
percentage of total demonstrated food consumed at the "post-lesion plus gaunfacine" 
time point. As the number of ChAT positive cells increased across subjects, memory 
performance similarly increased on the STFP task. This finding is extremely relevant 
because it suggests that a certain baseline number of ACh neurons within the medial 
septum must be present in order for guanfacine to produce effects on memory. 
Effectiveness of guanfacine seems to be dependent on a particular number of 
acetylcholine neurons. 
Guanfacine as a pharmacological agent: Alzheimer's disease 
Within the context of Alzheimer's disease, the observation that guanfacine is 
dependent on a specific basal number of acetylcholine cell numbers within the medial 
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septum is quite relevant. Note that Alzheimer's disease is correlated with gradual 
degeneration of acetylcholine neurons within the hippocampus; those cells responsible 
for the efficiency ofmemory performance (Bartus, 2000). Spontaneous and rapid 
deterioration of ACh neurons within an individual experiencing decreases in memory 
acquisition and recall is usually employed as diagnostic marker for dementia of the 
Alzheimer's type. Health care professionals, in the midst of suspecting AD, utilize the 
term "dementia" because AD remains diagnosable exclusively post-mortem via autopsy. 
In addition, the onset of dementia of the Alzheimer's type is particularly alarming 
because the loss of ACh neurons in AD is terminal. This means that increasing 
reductions in ACh cells ultimately contribute to death. Such imminent and unavoidable 
cell death has been proclaimed as the single greatest limiting factor when considering 
pharmacological treatment methods for dementia of the Alzheimer's type (Delagarza, 
2003). 
One such treatment method falls under the category of acetylcholinesterase 
inhibitors (AChE-I). Note that pharmacological agents of this genre exert beneficial 
therapeutic effects by inhibiting acetylcholinesterase (AChE), the enzyme responsible for 
degrading ACh neurotransmitters following post-synaptic binding. Inhibition of AChE 
leads to a decrease in hydrolysis ofACh thereby permitting increased ACh receptor 
stimulation. Ultimately increases in receptor activation presumably lead to increased 
memory performance, mainly during recall (Rogers, 1998). 
Increases in memory performance seem to be largely dependent on the number of 
active and surviving ACh neurons, since ACh neurons are responsible for transmission of 
information during information acquisition, storage, and recall. This observation alone is 
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evidence of the limiting application ofAChE-Is in that AChE can only be inhibited to the 
extent by which ACh cell survival exists. AChE-Is therefore do not protect against ACh 
cell death, they merely aid in the preservation ofmemory processing as long as a certain 
basal number of ACh neurons continue to function. 
The present study is harmonious with observations ofthe limiting nature of 
AChE-Is. More specifically, the behavioral effects of guanfacine, while not statistically 
significant (however, approaching significance), seem to be dependent on a certain 
number of surviving ACh cells within the medial septum. As a result, the norepinephrine 
agonist guanfacine possesses similar drawbacks associated with AChE-Is. Most likely, 
utilization of guanfacine in the treatment of dementia of the Alzheimer's type will only 
exert therapeutic effects for as long as ACh cells survive. 
Before entirely abandoning guanfacine as a plausible treatment approach to AD, 
the present significant increase in percentage of demonstrated food consumed within the 
"post-lesion plus guanfacine" treatment group is extremely relevant. Taking into 
perspective this value, it is likely that memory formation occurred following guanfacine 
injection. Since a similar significant value was not observed in the "post-lesion" group it 
is reasonable to assume that guanfacine likely contributed to a large degree in the onset of 
memory formation. It is probable that guanfacine may have restored the subjects' ability 
to form novel memories. 
Future research 
Restoration of memory formation following the administration of guanfacine, an 
alpha-2 norepinephrine agonist, in the present experiment contributes to the relevance of 
an animal model for Alzheimer's disease. Identifying the rat as a valid animal in which 
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to manipulate treatment approaches to AD is most likely the greatest result of the present 
study. Additionally, observations involving the reliance of guanfacine on a basal ACh 
neuron level lead to the conclusion that norepinephrine agonists might suffer from similar 
limitations associated with AChE-Is. In the seemingly never-ending quest to uncover 
safe, effective, and neuronal-protective pharmacological agents, future research must 
utilize precise methodology. 
As a result of the present experiment, future analysis must attempt to uncover the 
relationship between the adrenergic system and the cholinergic system within the STFP 
behavioral paradigm. Current results indicate that following administration of 
guanfacine, memory formation increased in the post-lesion group. However, whether NE 
axonal sprouting into the hippocampus was responsible for the return of memory 
formation could not be determined due to the absence of available NE histoflourescent 
staining materials. Obtaining such materials would allow one to measure the prevalence 
ofNE sprouting into the hippocampus by comparing levels to controls. 
Measurements ofNE axonal in-growth might then be analyzed with levels of 
surviving ACh neurons within the medial septum following saporin infusion. This would 
allow one to investigate the relationship between NE compensatory sprouting into the 
hippocampus in reaction to ACh cell death within the medial septum. Based on previous 
research, this would permit one to make comments on the compensatory hypothesis of 
interacting noradrenergic and cholinergic systems in animal subjects who display 
substantial Alzheimer's memory-type deficits. 
In addition, future research should examine the relationship between NE 
sprouting, ACh levels, and behavioral performance on the STFP task. This would allow 
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one to collectively evaluate the modulation of these components in a statistical analytical 
program, inspecting for correlations. It is likely that interactions exist between the ACh 
system, NE system, and a behavioral STFP-type paradigm as supported by previous 
research. 
Once relationships have been revealed between modulation of the cholinergic and 
adrenergic systems following ACh cell loss, studies involving NE agonists might take 
place. One stipulation of entering into such trials should rely on the observation that NE 
axonal sprouting occurs in compensation for ACh loss within the hippocampus. 
Following norepinehprine agonist administration (after saporin infusion) it would be 
beneficial to measure norepinephrine levels within the hippocampus via high 
performance liquid chromatography (HPLC). Norepinephrine levels might then be 
correlated to ACh levels within the hippocampus, measured via HPLC as well. One 
might expect decreased ACh levels within the hippocampus and increased NE levels due 
to the previously published compensatory nature ofNE axonal sprouting into the 
hippocampus (Crutcher & Davis, 1981; Crutcher & davis,198l; Madison & Davis, 1983). 
Norepinephrine and acetylcholine levels might then be correlated to behavioral 
performance on the STFP task, indicating increases in memory formation as a result of 
excess NE stimulation within the hippocampus following saporin lesion to the medial 
septum. 
Finally, the present investigation likely suffered from small control and 
manipulation group numbers. Low subject population numbers indisputably lead to a 
decrease in statistical power and large standard error values and as a result to a decrease 
in significant correlations between experimental and control groups. Future work should 
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ensure the survival of subject populations beyond the ones reported within this study. A 
power analysis examining the correlation between ChAT-positive cells and the post­
lesion plus Guanfacine-treated group, indicated that a subject population of 17 would be 
needed to attain a significant correlation. 
Final comments 
Since the onset of the "cholinergic hypothesis", considerable evidence has been 
obtained in support of impairment of the cholinergic system within Alzheimer's diseased 
patients (Bartus et aI., 1982). First, in the context ofleaming and memory tasks, 
predominant modulation ofmemory processing by acetylcholine has been shown to occur 
within the hippocampus (Dutar et aI., 1995). Numerous studies indicate that in human 
populations, Alzheimer's disease (AD) is marked by a lack of cholinergic transmission 
within the hippocampal region (Bartus et aI., 1982; Rossor et aI., 1981). The medial 
septal area, which exhibits neuronal projection to the hippocampus, has been implicated 
as the principal source of acetylcholine to the hippocampus (Vale-Martinez et aI., 2002). 
Consequently, lesioning the medial septum has produced widespread memory deficits via 
decreased availability of acetylcholine transmitters to the hippocampus (Potter et aI., 
1999). 
Undoubtedly, the adrenergic and cholinergic systems are clearly linked within the 
context of information acquisition and subsequent memory formation. One study by 
Kruglikov (1982) indicated that impairment did not exist on an avoidance memory task 
following administration of the cholinergic antagonist scopolamine. However, when 
scopolamine was administered in conjunction with locus coeruleus lesions, drastic 
impairment resulted. Another study by Harrell, Peagler, & Parsons (1990) presented data 
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that increases in impairment were exhibited by rats on a radial maze apparatus following 
administration of the beta-adrenergic antagonist propranolol in conjunction with medial 
septum lesions. Application ofpropranolol following lesion to the medial septum 
significantly worsened already decreased learning and memory performance. Moreover, 
numerous observations have been made that stimulation of the alpha-2 adrenergic 
receptor within the locus coeruleus likely accounts for increases on memory-related tasks 
(Amsten et aI., 1988; Arsten & Cai, 1993; lakala et aI., 1999). 
Final conclusions 
In light ofprevious theoretical framework, the present study reports three 
meaningful conclusions: (1) following infusion of saporin into the medial septum, 
memory formation for a socially transmitted food preference decreased significantly, (2) 
following administration of guanfacine after saporin infusion, memory formation for a 
socially transmitted food preference increased significantly, and (3) memory formation 
for a socially transmitted food preference following guanfacine administration is 
approaching significance when positively correlated to the number of surviving ACh 
cells following saporin infusion. 
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